• 1
    Ozkan M, Corapcioglu A, Balcioglu I et al. Psychiatric morbidity and its effect on the quality of life of patients with chronic hepatitis B and hepatitis C. Int J Psychiatry Med 2006; 36: 283297.
  • 2
    Navinés R, Castellví P, Moreno-España J et al. Depressive and anxiety disorders in chronic hepatitis C patients: reliability and validity of the Patient Health Questionnaire. J Affect Disord 2012; 138: 343351.
  • 3
    Fábregas BC, Vitorino FD, Rocha DM, Moura AS, Carmo RA, Teixeira AL. Screening inventories to detect depression in chronic hepatitis C patients. Gen Hosp Psychiatry 2012; 34: 4045.
  • 4
    Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003; 10: 8186.
  • 5
    McAndrews MP, Farcnik K, Calen P et al. Prevalence and significance of neurocognitive disfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801808.
  • 6
    Soogoor M, Lynn HS, Donfield SM et al. Hepatitis C virus infection and neurocognitive function. Neurology 2006; 67: 14821485.
  • 7
    Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol 2004; 78: 51705183.
  • 8
    Fishman SL, Murray JM, Eng FJ, Walewski JL, Morgello S, Branch AD. Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis 2008; 197: 597607.
  • 9
    Radkowski M, Bednarska A, Horban A et al. Infection of primary human macrophages with hepatitis C virus in vitro: induction of tumour necrosis factor-alpha and interleukin 8. J Gen Virol 2004; 85: 4759.
  • 10
    VanVlierberghe H, Adler M, Bastens B et al. Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust study. Acta Gastroenterol Belg 2010; 73: 511.
  • 11
    Sonneveld MJ, Janssen HL. Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B. Curr Hepat Rep 2010; 9: 9198.
  • 12
    Ogawa E, Furusyo N, Kajiwara E et al. The Kyushu University Liver Disease Study [KULDS] Group. Evaluation of the adverse effect of premature discontinuation of pegylated interferon alpha-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. J Gastroenterol Hepatol 2012; 27: 12331240.
  • 13
    Lang JP, Meyer N, Doffoel M. Benefits of a preventive psychiatric accompaniment in patients hepatitis C virus seropositive (HCV): prospective study concerning 39 patients. Encephale 2003; 29: 362365.
  • 14
    O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004; 19: 397403.
  • 15
    Goshen I, Yirmiya R. Interleukin-1 (IL-1): a central regulator of stress responses. Front Neuroendocrinol 2009; 30: 3045.
  • 16
    Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology 2009; 30: 497521.
  • 17
    Stasi C, Zignego AL, Laffi G, Rosselli M. The liver-cytokine-brain circuit in interferon-based treatment of patients with chronic viral hepatitis. J Viral Hepat 2011; 18: 525532.
  • 18
    Loftis JM, Huckans M, Ruimy S, Hinrichs DJ, Hauser P. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factoralpha. Neurosci Lett 2008; 430: 264268.
  • 19
    Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 47: 411418.
  • 20
    Miller HL, Delgado PL, Salomon RM, Licinio J, Barr LC, Charney DS. Acute tryptophan depletion: a method of studying antidepressant action. J Clin Psychiatry 1992; 53: 2835.
  • 21
    Comai S, Cavalletto L, Chemello L et al. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C. Pharmacol Res 2011; 63: 8592.
  • 22
    Hughes MM, Carballedo A, McLoughlin DM et al. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav Immun 2012; 26: 979987.
  • 23
    Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95: 26982709.
  • 24
    Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 2003; 3: S2534.
  • 25
    Varnäs K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 2004; 22: 246260.
  • 26
    Mawe GM, Branchek TA, Gershon MD. Peripheral neural serotonin receptors: identification and characterization with specific antagonists and agonists. Proc Natl Acad Sci U S A 1986; 83: 97999803.
  • 27
    Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993; 60: 23192322.
  • 28
    Olivier B, Soudijn W, Van Wijngaarden I. Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors. Prog Drug Res 2000; 54: 59119.
  • 29
    Lesurtel M, Graf R, Aleil B et al. Platelet-derived serotonin mediates liver regeneration. Science 2006; 312: 104107.
  • 30
    Capece L, Arrar M, Roitberg AE, Yeh SR, Marti MA, Estrin DA. Substrate Stereo-specificity in Tryptophan dioxygenase and Indoleamine 2,3- dioxygenase. Proteins 2010; 78: 29612972.
  • 31
    Larrea E, Riezu-Boj JI, Gil-Guerrero L et al. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol 2007; 81: 36623666.
  • 32
    Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7: 11151119.
  • 33
    Kamata M, Suzuki A, Yoshida K, Takahashi H, Higuchi H, Otani K. Genetic polymorphisms in the serotonergic system and symptom clusters of major depressive disorder. J Affect Disord 2011; 135: 374376.
  • 34
    Pissurlenkar RS, Dhir A, Kessar SV, Kulkarni SK, Coutinho EC. An activity model for novel antidepressants that interact with the serotonin transporter (SERT). Cent Nerv Syst Agents Med Chem 2011; 11: 228237.
  • 35
    Shih JC, Chen K. MAO-A and -B gene knockout distinctly different behavior. Neurobiology (Bp) 1999; 7: 235246.
  • 36
    Shimizu T, Kouketsu K. Metabolism of 5-Hydroxytryptamine in acidified platelets concentrates. Jpn J Pharmacol 1988; 46: 147153.
  • 37
    Kvetnoy IM. Extrapineal melatonin: location and role within diffuse neuroendocrine system. Histochem J 1999; 31: 112.
  • 38
    Cozzi A, Zignego AL, Carpendo AR et al. Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat 2006; 13: 402408.
  • 39
    Capuron L, Neurauter G, Musselman DL et al. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry 2003; 54: 906914.
  • 40
    Maes M, Bonaccorso S, Marino V et al. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry 2001; 6: 475480.
  • 41
    Bonaccorso S, Marino V, Puzella A et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 8690.
  • 42
    Zignego AL, Cozzi A, Carpenedo R et al. HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. Dig Liver Dis 2007; 39: S107111.
  • 43
    Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 26212624.
  • 44
    Lotrich FE, Pollock BG. Meta-analysis of serotonin transporter polymorphisms and affective disorder. Psychiatr Genet 2004; 14: 121129.
  • 45
    Hoefgen B, Schulze TG, Ohlraun S et al. The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol Psychiatry 2005; 57: 247251.
  • 46
    Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009; 65: 344348.
  • 47
    Pierucci-Lagha A, Covault J, Bonkovsky HL et al. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics 2010; 51: 137148.
  • 48
    Zalsman G, Huang Y, Oquendo MA et al. Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am J Psychiatry 2006; 163: 15881593.
  • 49
    Sharp T, Gartside SE, Umbers V. Effects of co-administration of a monoamine oxidase inhibitor and a 5-HT1A receptor antagonist on 5-hydroxytryptamine cell firing and release. Eur J Pharmacol 1997; 320: 1519.
  • 50
    Schaëfer A, Scheurlen M, Seufert J et al. Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression. J Hepatol 2010; 52: 1015.
  • 51
    Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 52
    Bruno S, Vierling JM, Esteban R et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol 2013; 58: 479487.
  • 53
    Zeuzem S, Andreone P, Pol S et al. Realize trial final results: telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to pegylated IFN and ribavirin. J Hepatol 2011; 54: S3.
  • 54
    Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b. Clin Drug Investig 2006; 26: 655662.
  • 55
    Bagheri H, Fouladi A, Barange K et al. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. Pharmacotherapy 2004; 24: 15461553.
  • 56
    Yu ML, Dai CY, Lee LP et al. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy. Antivir Ther 2006; 11 (8): 10151019.
  • 57
    Lang JP, Halleguen O, Vecchionacci V, Doffoel M. Reflections on the treatment of EDM in hepatitis C virus patients treated with interferon alpha from a retrospective survey concerning 29 patients. Encephale 2003; 29 (3 Pt 1): 273277.
  • 58
    Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000; 173: 359361.
  • 59
    Kraus MR, Schäfer A, Schöttker K et al. Therapy of interferon-induced depression in chronic hepatitis c with citalopram: a randomized, double-blind, placebo-controlled study. Gut 2008; 57: 531536.
  • 60
    de Knegt RJ, Bezemer G, Van Gool AR et al. Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2011; 34: 13061317.
  • 61
    Burke WJ, Kratochvil CJ. Stereoisomers in psychiatry: the case of escitalopram. Prim Care Companion J Clin Psychiatry 2002; 4 (1): 2024.
  • 62
    Schaëfer M, Hinzpeter A, Mohmand A et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007; 46: 991998.
  • 63
    Schaëfer M, Schwaiger M, Garkisch AS et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42: 793798.
  • 64
    Morasco BJ, Loftis JM, Indest DW et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics 2010; 51: 401408.
  • 65
    National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults. (update). Final draft, October 2009. Available at: Accessed October 2009.
  • 66
    Kaplan HI, Sadock BJ, Grebb JA. Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences Clinical Psychiatry, 7th edn. Baltimore, MD: Williams & Wilkins, 1994.
  • 67
    Schaefer M, Capuron L, Friebe A et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 2012; 57: 13791390.
  • 68
    Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry 2004; 161: 429435.
  • 69
    Greenberg DB, Jonasch E, Gadd MA et al. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 2000; 89: 356362.
  • 70
    Wu PL, Liao KF, Peng CY, Pariante CM, Su KP. Manic episode associated with citalopram therapy for interferon-induced depression in a patient with chronic hepatitis C infection. Gen Hosp Psychiatry 2007; 29: 374376.
  • 71
    EASL. 2012. Interferon lambda beats alfa in clearing HCV genotype 2 or 3. From Medscape Medical News. Available at: Accessed April 27, 2012.
  • 72
    Chan HL, Ren H, Chow WC, Wee T. Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. Hepatology 2007; 46: 315323.
  • 73
    Han Q, Liu Z, Kang W, Li H, Zhang L, Zhang N. Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial. Dig Dis Sci 2008; 53: 22382245.
  • 74
    Arase Y, Suzuki Y, Suzuki F et al. Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients. Intern Med 2011; 50: 20832088.